Sutro Biopharma
STRO
Sutro Biopharma (STRO) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.40
- EPS estimate
- −$3.82
- EPS surprise
- +63.39%
- Revenue surprise
- +302.50%
- Revenue
- $63.7M
- Revenue estimate
- $15.8M
- Reported
- Aug 7, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$3.82 | −$1.40 | +63.39% | $63.7M | SEC |
| Q1 2025 | May 8, 2025 | −$6.43 | −$9.10 | −41.62% | $17.4M | SEC |
| Q4 2024 | Mar 13, 2025 | −$8.30 | −$8.30 | +0.05% | $14.8M | SEC |
| Q3 2024 | Nov 13, 2024 | −$7.35 | −$5.90 | +19.68% | $8.5M | SEC |
| Q2 2024 | Aug 13, 2024 | −$7.92 | −$5.90 | +25.47% | $25.7M | SEC |
| Q1 2024 | May 13, 2024 | −$9.22 | −$9.50 | −3.08% | $13.0M | SEC |
| Q4 2023 | Mar 25, 2024 | −$2.71 | $5.20 | +291.69% | $113.7M | SEC |
| Q3 2023 | Nov 13, 2023 | −$7.36 | −$8.10 | −10.05% | $16.9M | SEC |
| Q2 2023 | Aug 10, 2023 | −$7.33 | −$6.40 | +12.63% | $10.4M | SEC |
| Q1 2023 | May 15, 2023 | −$7.84 | −$8.50 | −8.45% | $12.7M | SEC |
| Q4 2022 | Mar 30, 2023 | −$6.21 | −$5.90 | +5.03% | $8.6M | SEC |
| Q3 2022 | Nov 8, 2022 | −$2.89 | −$3.70 | −28.14% | $25.1M | SEC |
| Q2 2022 | Aug 8, 2022 | −$6.44 | −$5.50 | +14.63% | $28.1M | SEC |
| Q1 2022 | May 9, 2022 | −$7.57 | −$8.40 | −10.90% | $5.9M | SEC |
| Q4 2021 | Feb 28, 2022 | −$7.59 | −$8.30 | −9.33% | $10.4M | SEC |
| Q3 2021 | Nov 10, 2021 | −$6.51 | −$6.70 | −2.87% | $8.5M | SEC |
| Q2 2021 | Aug 9, 2021 | −$4.14 | −$1.30 | +68.60% | $28.0M | SEC |
| Q1 2021 | May 7, 2021 | −$6.23 | −$6.60 | −5.88% | $14.7M | SEC |
| Q4 2020 | Mar 18, 2021 | −$5.70 | −$15.40 | −170.18% | $8.3M | SEC |
| Q3 2020 | Nov 5, 2020 | −$5.07 | $4.50 | +188.73% | $17.8M | SEC |
Quarterly revenue
Frequently asked questions
When did Sutro Biopharma (STRO) last report earnings?
Sutro Biopharma last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did STRO beat earnings estimates?
Yes. Sutro Biopharma reported EPS of −$1.40 for Q2 2025 against a −$3.82 estimate — a 63.39% beat.
How much revenue did STRO report last quarter?
Sutro Biopharma reported $63.7M in revenue for Q2 2025, against a consensus estimate of $15.8M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.